

Brian Eyden • S. Sankar Banerjee
Yongxin Ru • Paweł Liberski

The Ultrastructure of Human Tumours

Applications in Diagnosis and Research



ZHEJIANG UNIVERSITY PRESS
浙江大学出版社

 Springer

Brian Eyden
S. Sankar Banerjee
Yongxin Ru
Paweł Liberski

The Ultrastructure of Human Tumours

Applications in Diagnosis and Research

With 757 figures, 1 of them in colour

图书在版编目(CIP)数据

人体肿瘤超微结构在其诊断及研究中的应用=The
Ultrastructure of Human Tumours: Applications in
Diagnosis and Research: 英文 / (英)艾登等著. —
杭州: 浙江大学出版社, 2013.6
ISBN 978-7-308-10626-9

I. ①人… II. ①艾… III. ①肿瘤-超微结构-研究
-英文 IV. ①R730.21

中国版本图书馆CIP数据核字(2012)第222083号

Not for sale outside Mainland of China

此书仅限中国大陆地区销售

人体肿瘤超微结构在其诊断及研究中的应用

布莱恩·艾登 桑卡尔·巴纳吉 茹永新 帕维尔·利伯斯基 著

责任编辑 张凌静(zlj@zju.edu.cn)

封面设计 俞亚彤

出版发行 浙江大学出版社

网址: <http://www.zjupress.com>

Springer-Verlag GmbH

网址: <http://www.Springer.com>

排版 杭州金旭广告有限公司

印刷 浙江印刷集团有限公司

开本 880mm×1230mm 1/16

印张 43.5

字数 1430 千

版印次 2013年6月第1版 2013年6月第1次印刷

书号 ISBN 978-7-308-10626-9(浙江大学出版社)

ISBN 978-3-642-39167-5(Springer-Verlag GmbH)

定价 398.00 元

版权所有 翻印必究 印装差错 负责调换

浙江大学出版社发行部联系方式 (0571) 88925591; <http://zjdxcs.tmall.com>

Authors

Dr. Brian Eyden
Department of Histopathology
Christie NHS Foundation Trust
Manchester M20 4BX, United Kingdom
E-mail: brian.p.eyden@hotmail.co.uk

Dr. S. Sankar Banerjee
Department of Histopathology
Christie NHS Foundation Trust
Manchester M20 4BX, United Kingdom
E-mail: ssbanerjee.uk@gmail.com

Dr. Yongxin Ru
Department of Electron Microscopy
Institute of Haematology and Blood Diseases Hospital
Tianjin 300020, China
E-mail: ruyongxin@126.com

Prof. Paweł Liberski
Department of Molecular Pathology and Neuropathology
Medical University Łódź
90-419 Łódź, Poland
E-mail: ppliber@csk.am.Lodz.pl

ISBN 978-7-308-10626-9
Zhejiang University Press, Hangzhou

ISBN 978-3-642-39167-5
Springer Heidelberg New York Dordrecht London

e-ISBN 978-3-642-39168-2

Library of Congress Control Number: 2013941472

© Zhejiang University Press, Hangzhou and Springer-Verlag Berlin Heidelberg 2013

This work is subject to copyright. All rights are reserved by the Publishers, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publishers' locations, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publishers can accept any legal responsibility for any errors or omissions that may be made. The publishers make no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

Abbreviations

ACTH	adrenocorticotrophic hormone
AFX	atypical fibroxanthoma
AGG	angioganglioglioma
AIDS	acquired immunodeficiency syndrome
ALCL	anaplastic large-cell lymphoma
ALL	acute lymphoblastic leukaemia
AML	acute myeloid leukaemia
APL	acute promyelocytic leukaemia
ASPS	alveolar soft-part sarcoma
ATCLL	adult T-cell leukaemia/lymphoma
AT/RT	atypical teratoid/rhabdoid tumour
AVM	arteriovenous malformation
BCC	basal-cell carcinoma
CADASIL	cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
CE	chloroacetate esterase
CEL	chronic eosinophilic leukaemia
CLL	chronic lymphocytic leukaemia
CML	chronic myelogenous leukaemia
CNS	central nervous system
CPC	choroid plexus carcinoma
CPP	choroid plexus papilloma
DCAI	desmoplastic cerebral astrocytoma of infancy
DFSP	dermatofibrosarcoma protuberans
DIA	desmoplastic infantile astrocytoma
DIG	desmoplastic infantile ganglioglioma
DLBCL	diffuse large B-cell lymphoma
DMM	desmoplastic malignant melanoma
DMS	demarcation membrane system
DNM	desmoplastic neurotropic melanoma
DNT	dysembryoplastic neuroepithelial tumour
DRC	dendritic reticulum cell
EHD	eosinophilic hyaline droplet
EMA	epithelial membrane antigen
FAB	French, American and British
FEAM	focus of extracellular amorphous matrix
GANT	gastrointestinal autonomic nerve tumour
GCA	granular-cell astrocytoma
GCG	granular-cell glioblastoma
GCT	giant-cell tumour
GFAP	glial fibrillary acidic protein
GI	gastrointestinal
GIST	gastrointestinal stromal tumour
H&E	haematoxylin and eosin
HCL	hairy cell leukaemia
HL	Hodgkin Lymphoma
HIV	human immunodeficiency virus
HMB-45	human melanoma black 45

ICC	interstitial cell of Cajal
Ig	immunoglobulin
IHC	immunohistochemistry
IMS (IMT)	inflammatory myofibroblastic sarcoma (tumour)
LC	Langerhans cell
LCG	Langerhans cell granule
L-DOPA	L-3,4-dihydroxyphenylalanine
LGFMS	low-grade fibromyxoid sarcoma
LGM	low-grade myofibrosarcoma
MAG	monomorphous angiocentric glioma
MBP	myelin basic protein
MFH	malignant fibrous histiocytoma
MGB	Michaelis-Gutmann body
MGC	multinucleated giant cell
ML	malignant lymphoma
MNTI	melanotic neuroectodermal tumour of infancy
MPNST	malignant peripheral nerve sheath tumour
MPO	myeloperoxidase
MTS	membrane tubule system
MVB	multivesicular body
NAS-DAE	naphthol AS-D acetate esterase
NMM	neurotropic malignant melanoma
NOS	not otherwise specified
NSE	neuron specific enolase
NSE	non-specific esterase
OLC	oligodendrocyte-like cell, oligodendroglial-like cell
PA	pilocytic astrocytoma
PAS	periodic acid-Schiff
PB	pineoblastoma
PC	pineocytoma
PEC	perivascular epithelioid cell
PEComa	perivascular epithelioid cell tumour
PEL	pleural effusion lymphoma
PGNT	papillary glioneuronal tumour
PHAT	pleomorphic hyalinising angiectatic tumour
PLL	prolymphocytic leukaemia
PMA	pilomyxoid astrocytoma
PNET	peripheral primitive neuroectodermal (neuroepithelial) tumour
PNST	peripheral nerve-sheath tumour
POX	peroxidase
PPO	platelet peroxidase
PPT	pineal parenchymal tumour
PPTID	pineal parenchymal tumour of intermediate differentiation
PXA	pleomorphic xanthoastrocytoma
rER	rough endoplasmic reticulum
RGB	round granular body
RGNT	rosette-forming glioneuronal tumour
RS	Reed-Sternberg
SCC	squamous-cell carcinoma
SCAI	superficial cerebral astrocytoma of infancy
SBB	Sudan Black B
SEGA	subependymal giant-cell astrocytoma
sER	smooth endoplasmic reticulum
SFT	solitary fibrous tumour
SMA	α -smooth-muscle actin
SRC	signet-ring cell
VCR	vesicle-crowned rodlet
vs	versus
WHO	World Health Organisation
WPB	Weibel-Palade body
YST	yolk sac tumour

Acknowledgements

As the senior author and originator of the idea for this book, I would like to thank my co-authors – Dr S Sankar Banerjee (Manchester, United Kingdom), Dr Yongxin Ru (Tianjin, China) and Professor Paweł Liberski (Łódź, Poland) – for their commitment not only to this book, but also, over many years, to electron microscopy in the service of patients and science. I wish also to express my most sincere thanks to the other pathologists in the Department of Histopathology at the Christie NHS Foundation Trust – Lia Patricia Menasce, Jonathan Shanks, Patrick Shenjere and Bipasha Chakrabarty – who, as the friendliest and most professional of colleagues, provided the framework of classical pathology without which the ultrastructural pathology of tumours has limited meaning. This is an opportunity also to express my deep appreciation of three professors of pathology – Peter Toner (Glasgow and Belfast), Cyril Fisher (London) and Irving Dardick (Toronto) – who, at different times in my career, provided encouragement and support.

My additional thanks go to the several editors who have granted permission to reproduce figures originally published in their journals. Especial thanks go to Laura Neri of Nuova Immagine Editrice (Siena, Italy) for giving permission to re-use in this book a large number of figures originally published in my 2007 monograph on the myofibroblast, and to Igaku-Shoin Ltd (Tokyo) for their kind permission to use a similarly not insignificant number of images from my 1996 book on tumour cell organelles.

I would like to express a deep appreciation of the following scientists and pathologists who have kindly provided micrographs for this book, or grids of sections or blocks to study: Dr Alex Berndt (Jena, Germany), Dr Birgitta Carlén (Lund, Sweden), Dr Kathy Chorneyko (Hamilton, Canada), Dr Alan Curry (Manchester, United Kingdom), Professor Irving Dardick (Toronto, Canada), Professor Meir Djaldetti (Petah-Tiqva, Israel), Professor MS Faussone-Pellegrini (Florence), Professor Cyril Fisher (London, United Kingdom), Dr Mihaela Gherghiceanu (Bucharest, Romania), Dr Carolyn Jones (Manchester, United Kingdom), Professor Hartwig Kosmehl (Erfurt, Germany), Professor Karin Löffler (Bonn), Professors José A López García-Asenjo and Julia Blanco Gonzalez (Madrid), Dr Kuwashima (Japan), Professor Bruce Mackay (Houston, Texas), Professor Michal Michal (Pilsen, Czech Republic), Dr Gary Mierau (Denver, United States of America), Dr T Nakatani (Toyama, Japan), Dr Barbara Schneider and Professor Ursula Schnyder (Zürich, Switzerland) and Dr Kazuto Yamazaki (Tokyo).

Finally, my thanks and love go to my elder daughter, Joanna, for scanning negatives, my younger daughter, Suzy, for word-processing references, and my wife, Freda, for her invaluable support and understanding during the writing of this book.

My co-authors will want to join me in thanking Dr Wu Xiufang and Mrs Zhang Lingjing of Zhejiang University Press, Hangzhou, China, for their friendly and competent assistance in the realisation of this book; Mr Paul Chantry of the Medical Illustration Department at the Christie Hospital, Manchester, for drawing the fibronexus of Fig. 4.8, and last but not least, Mrs Collette Curry; her many points of assistance and advice in computerised image handling significantly facilitated the preparation of this book.

Brian Eyden
Manchester, UK
February, 2013

Preface

Electron microscopy is one of the great techniques developed in the twentieth century with applications in the biological sciences, and it has played its part in revolutionising the way we understand the structure and function of cells and tissues. Following its development in the 1930s, electron microscopy was applied to biological specimens, including human tissues modified by disease, initially for the purposes of research. In the 1960s, however, it became clear that electron microscopy could also have diagnostic value in medicine, since it was found that particular diseases had characteristic ultrastructural features. Applications were found in renal, neuromuscular, storage and ciliary diseases, infectious microorganisms, and tumours, to mention perhaps the most important areas. With regard to tumours, it was found that distinctive cell organelles were identifiable which could help tumour pathologists assess cell differentiation more accurately and lead to more secure diagnoses. From the 1960s to 1980s, electron microscopy was a major ancillary technique in the diagnosis of human tumours, following the classical technique of histological sections stained in haematoxylin and eosin and special stains.

The 1980s saw a significant change in the way pathologists approached the diagnosis of tumours, principally through the introduction at this time of the technique of immunohistochemistry (IHC). The use of labelled antibodies believed to be cell-lineage specific became a convenient and preferred technique, and electron microscopy suffered a significant loss of importance, with re-allocation of funding towards IHC and the closure of many clinical electron microscopy units. However, it has become clear that there are very few completely specific antibodies, a limitation of IHC requiring compensation in the form of sometimes large (and expensive) panels of immunostains in order to secure confident interpretation and diagnosis. Other limitations of IHC have become apparent – the minimal immunoreactivity of certain neoplasms, especially those showing fibroblastic differentiation; the obtaining of different results for the same antibody in different laboratories; the difficulty in sometimes distinguishing weak-positive from negative staining; and the differences in results due to changing instrumentation and technique. As a result, tumours are still encountered where there is interpretational uncertainty, and here, electron microscopy can provide additional information, which can be useful for reaching a more accurate final diagnosis, on which, after all, appropriate treatment of the patient depends.

In the belief that electron microscopy is still useful for pathologists who need precise diagnoses for the tumours they encounter in their day-to-day routine practice, as well as for scientists and doctors engaged in cancer research on *in vivo* and *in vitro* material (such as cancer cell lines and tumours in laboratory animals), we have written this atlas of tumour ultrastructure. The essential feature and objective is to add our own direct experience – our own observations and interpretations – to the existing literature. Certainly, some of our observations will be familiar to the ultrastructurally oriented reader, and these observations will constitute a confirmation of existing data – a not unimportant aspect of scientific work. More significantly, however, our book also includes new images of familiar tumours, as well as images of newly described variants – all providing novel perspectives on tumour cell differentiation. Wherever possible, we have also incorporated images of normal cells to provide information on the ‘normal cellular counterpart’ of tumours, which we believe is important for understanding tumour cell differentiation. In addition, our ultrastructural images are presented in the context of classical tumour pathology, with brief introductory comments on histology, immunophenotype and differential diagnosis. Rather than being a comprehensive bible of named tumours, our work is aimed at emphasising the core ultrastructural features defining a given tumour cell differentiation, as a passport through the seemingly infinite complex territory of tumour pathology and ultrastructure – in short, we want to put across the grammar of ultrastructural pathology applied to tumours, rather than a comprehensive vocabulary.

Because the book is based on our own micrographic data, there is some selectivity in the material illustrated. For tumours outside our own direct experience, our friendly colleagues have supplied some images, but otherwise, we have resorted to citing the published literature. Here again, the enormous literature on the ultrastructure of human tumours – as many as 36,000 papers according to a current Pubmed search – has forced us to be selective. Certainly, we have found it sensible to mention publications from the more accessible journals – the American Journal of Surgical Pathology, Human Pathology, Histopathology and Virchows Archiv – and understandably we have also relied particularly on the specialised journal, Ultrastructural Pathology. Although not an easy task, we have also tried to balance the older and the more recent literature. The early literature often gives more extensive ultrastructural descriptions, but can harbour out-dated terminology and concepts: by contrast, the more recent literature is more likely to offer a more meaningful immunohistochemical context, inevitably absent from the earlier ultrastructural papers, which in any case are mentioned in pre-existing monographs. In short, we extend our apologies to the authors of the many papers deserving of mention that we have not found it possible to cite.

There is so much that we still do not understand about tumour cell differentiation – about the nature and function of the structures we see during our routine diagnostic practice. Along with other exponents of electron microscopy (to be found among the references), we hope that the book will inspire investigators to study the biology of human tumours by methods which will include electron microscopy, to produce results which will enhance our understanding of tumour cell differentiation, which, in turn, might impact positively not only on diagnostic precision but also understanding the mechanism of cancer with consequences for developing therapeutic strategies.

Brian Eyden and S. Sankar Banerjee
(Manchester, United Kingdom)

Yongxin Ru
(Tianjin, China)

Paweł Liberski
(Łódź, Poland)

February, 2013

Contents

1 Introduction

1.1	Introductory Remarks	1
1.2	Electron Microscopy Applied to Tumours	1
1.3	Impact and Limitations of Immunohistochemistry	3
1.4	Value of Electron Microscopy in Addition to Diagnosis	3
1.5	Intellectual Basis for Tumour Diagnosis by Electron Microscopy	4
1.6	Technique	4
1.6.1	Tissue Handling and Reagent Preparation	4
1.6.2	Electron Microscopy Procedure	5
1.6.3	Dewaxing for Electron Microscopy	6
1.7	Assessing the Quality of Preservation in Semi-thin Sections	7
1.8	Distinguishing Reactive from Neoplastic Cells	10
1.8.1	Vessels	10
1.8.2	Myofibroblasts	13
1.8.3	Striated Muscle Cells	14
	References	15

2 Epithelial Tumours 17

2.1	Introductory Remarks	17
2.2	The Core Features of Epithelial Differentiation	17
2.3	The Keratinocyte as the Archetypal Cell for Assessing Basal-Cell and Squamous-Cell Differentiation in Tumours	18
2.4	Basal-Cell and Squamous-Cell Carcinoma	18
2.4.1	Conventional Basal-Cell and Squamous-Cell Carcinoma	21
2.4.2	Variants of Basal-Cell Carcinoma	21
2.4.3	Poorly Differentiated Squamous-Cell Carcinoma, Variants of Squamous-Cell Carcinoma, and Related Tumours Showing Squamous Differentiation	21
2.5	Ultrastructural Features of Glandular Differentiation	30
2.5.1	Ultrastructural Architecture of the Normal Gland	30
2.5.2	Secretory Materials of Epithelial Origin	35
2.6	The Ultrastructure of Adenocarcinoma	43
2.6.1	General Ultrastructural Properties of Adenocarcinoma	43
2.6.2	Additional Features of Diagnostic or Biological Interest in Selected Examples of Adenocarcinoma and Carcinomas Showing Glandular Epithelial Differentiation	46
2.7	Tumours Showing Distinctive Specialised Forms of Epithelial Differentiation	60
2.7.1	Mesothelioma	60
2.7.2	Adrenocortical Tumours	70
2.7.3	Oncocytoma	71

2.7.4	Myoepithelial Cell Differentiation in Tumours.....	78
2.7.5	Neuroendocrine Differentiation in Carcinoma.....	79
	References.....	90
3	Melanocytic Lesions with Special Reference to Malignant Melanoma.....	105
3.1	Introductory Remarks	105
3.2	The Normal Melanocyte	106
3.3	The Ultrastructure of Malignant Melanoma.....	106
3.3.1	The Melanosome.....	108
3.3.2	Ultrastructural Features of Malignant Melanoma in Addition to Melanosomes.....	121
3.3.3	The Ultrastructure of Malignant Melanoma Variants	122
3.3.4	Tumours other than Malignant Melanoma Showing Melanocytic Differentiation	158
	References.....	167
4	Tumours of Soft Tissue and Bone, and Other Mesenchymal Tumours	177
4.1	Introductory Remarks	177
4.2	Fibroblastic and Myofibroblastic Tumours.....	177
4.2.1	The Normal Fibroblast and the Reactive Myofibroblast.....	178
4.2.2	Tumours and Tumour-Like Lesions Showing Fibroblastic Differentiation	184
4.2.3	Myofibroblastic Differentiation in Tumours and Tumour-Like Lesions	207
4.3	Fibrohistiocytic Tumours	224
4.3.1	Giant-Cell Tumours	225
4.3.2	The Benign Fibrous Histiocytomas.....	225
4.3.3	Plexiform Fibrohistiocytic Tumour	225
4.3.4	The So-Called Malignant Fibrous Histiocytomas.....	225
4.3.5	Atypical Fibroxanthoma	235
4.4	Smooth-Muscle Tumours and Pericytic Tumours.....	243
4.4.1	The Normal Smooth-Muscle Cell.....	243
4.4.2	Leiomyoma – Glomus Tumour.....	243
4.4.3	Myopericytoma/Haemangiopericytoma.....	244
4.4.4	Leiomyosarcoma.....	244
4.5	Tumours Showing Striated-Muscle Differentiation	256
4.5.1	The Normal Striated-Muscle Cell.....	256
4.5.2	Rhabdomyoma	256
4.5.3	Rhabdomyosarcoma.....	256
4.5.4	Rhabdomyoblasts in Tumours other than Rhabdomyoma and Rhabdomyosarcoma.....	257
4.6	Gastrointestinal Stromal Tumours	267
4.6.1	The Interstitial Cell of Cajal	267
4.6.2	The Ultrastructure of GIST	268
4.7	Vascular Tumours	286
4.7.1	The Normal Vessel	286
4.7.2	Benign Vascular Lesions	287
4.7.3	Conventional Angiosarcoma.....	287
4.7.4	Epithelioid Angiosarcoma	287
4.7.5	Epithelioid Haemangioendothelioma.....	291
4.7.6	Kaposi's Sarcoma	291
4.8	Adipocytic Tumours	300
4.8.1	The Normal Adipocyte	300
4.8.2	Benign Adipocytic Tumours.....	301
4.8.3	Liposarcoma	301

4.9	Tumours Showing Cartilaginous, Osteogenic and Notochordal Differentiation.....	309
4.9.1	Normal Cells of Cartilage and Bone	309
4.9.2	Benign Chondroblastic Lesions	310
4.9.3	Chondrosarcoma and Other Cartilaginous Tumours.....	310
4.9.4	Notochordal Tumours	311
4.9.5	Osteosarcoma and Other Osteogenic Tumours.....	319
4.10	Tumours Showing Complex or Uncertain Differentiation	322
4.10.1	Ossifying Fibromyxoid Tumour	322
4.10.2	Mixed Tumour/Myoepithelioma.....	322
4.10.3	Synovial Sarcoma	323
4.10.4	Epithelioid Sarcoma.....	323
4.10.5	Alveolar Soft-Part Sarcoma	324
4.10.6	Desmoplastic Small-Round-Cell Tumour.....	325
4.10.7	Malignant Rhabdoid Tumour.....	325
	References.....	341
5	Lymphoma and Leukaemia.....	363
5.1	Introductory Remarks	363
5.2	Normal (Reactive) Haematolymphoid Cells	364
5.2.1	Lymphocytes.....	364
5.2.2	Centroblasts and Centrocytes.....	367
5.2.3	Plasma Cells.....	368
5.2.4	Monocytes, Macrophages, Langerhans Cells and Multinucleated Giant Cells	369
5.2.5	Mast Cells	381
5.2.6	Eosinophils	382
5.2.7	Neutrophils	382
5.2.8	Basophils.....	382
5.2.9	Megakaryocytes and Platelets.....	391
5.2.10	Erythroblasts ('normoblasts' and 'normocytes').....	392
5.3	Haematolymphoid Neoplasia	395
5.3.1	Myeloproliferative Neoplasms.....	396
5.3.2	The Acute Leukaemias	397
5.3.3	B-Cell Neoplasms	410
5.3.4	T-Cell Neoplasms	442
5.3.5	Hodgkin Lymphoma	460
5.3.6	Tumours Showing Histiocytic Differentiation – Dendritic Cell Tumours	461
5.3.7	Reticulum Cell Tumours.....	475
	References.....	480
6	Tumours of the Central Nervous System	491
6.1	Introductory Remarks	491
6.2	Astrocytic Tumours.....	491
6.2.1	Astrocytoma.....	494
6.2.2	Glioblastoma.....	494
6.2.3	Pilocytic Astrocytoma.....	496
6.2.4	Pilomyxoid Astrocytoma	498
6.2.5	Pleomorphic Xanthoastrocytoma.....	498
6.2.6	Monomorphous Angiocentric Glioma	500
6.2.7	Subependymal Giant-Cell Astrocytoma of Tuberous Sclerosis.....	500
6.3	Oligodendroglioma	502

6.4	Ependymoma and Subependymoma	503
6.5	Choroid Plexus Tumours	507
6.6	Mixed Neuronal and Glial Tumours	509
6.6.1	Gangliocytoma and Ganglioglioma	509
6.6.2	Desmoplastic Infantile Ganglioglioma/Desmoplastic Cerebral Astrocytoma of Infancy or Desmoplastic Infantile Astrocytoma	512
6.6.3	Angioganglioglioma	514
6.6.4	Dysembryoplastic Neuroepithelial Tumour	515
6.6.5	Central Neurocytoma	518
6.6.6	Extraventricular Neurocytoma	519
6.6.7	Papillary Glioneuronal Tumour	519
6.6.8	Glioneuronal Tumour with Neuropil-Like Islands/Rosetted Glioneuronal Tumour	520
6.6.9	Rosette-Forming Glioneuronal Tumour of the IV th Ventricle	520
6.7	Pineal Parenchyma Tumours	520
6.7.1	Pineocytoma	520
6.7.2	PPT of Intermediate Differentiation	522
6.7.3	Pineoblastoma	523
6.7.4	Papillary Tumour of the Pineal Region	523
6.8	Embryonal Tumours	523
6.8.1	Medulloepithelioma	523
6.8.2	Ependymoblastoma	523
6.8.3	Medulloblastoma	523
6.8.4	Atypical Teratoid/Rhabdoid Tumour	527
6.8.5	Melanotic Neuroectodermal Tumour of Infancy	528
6.9	Meningioma and Meningioangiomatosis	528
6.10	Intracranial Germ Tumours	531
6.10.1	Germinomas	531
6.10.2	Yolk Sac Tumour	532
6.10.3	Embryonal Carcinoma	532
6.10.4	Choriocarcinoma	532
6.11	Craniopharyngioma	534
6.12	Paraganglioma	534
6.13	Cerebellar Liponeurocytoma	535
	Acknowledgements	535
	References	537
7	Tumours of the Neuroendocrine System and the Peripheral Nervous System	547
7.1	Introductory Remarks	547
7.2	The Ultrastructure of Neuroendocrine Tumours	548
7.2.1	The Archetypal Neuroendocrine Granule	548
7.2.2	Variations in the Structure of Neuroendocrine Granules in Different Neuroendocrine Tumours, and Additional Ultrastructural Features of Neuroendocrine Tumours	552
7.3	Tumours of the Peripheral Nervous System	577
7.3.1	The Normal Neuron	577
7.3.2	Extracranial Tumours Showing Neuronal/Glial/Ganglionic Differentiation	579
7.3.3	The Normal Nerve Sheath	595
7.3.4	Tumours of the Nerve Sheath	601
7.4	Meningioma	618
	References	624

8	Miscellaneous Tumours and Tumour-Like Lesions.....	643
8.1	Introductory Remarks	643
8.2	Tumours of the Male and Female Reproductive Tracts	643
8.2.1	Seminoma	643
8.2.2	Embryonal Carcinoma	644
8.2.3	Endodermal Sinus Tumour (Yolk Sac Tumour)	644
8.2.4	Choriocarcinoma.....	644
8.2.5	Tumours Showing Leydig-Cell Differentiation	644
8.2.6	Tumours Showing Sertoli-Cell Differentiation.....	645
8.2.7	Tumours Showing Granulosa-Cell Differentiation	645
8.3	Blastemal Tumours	657
8.3.1	Wilms' Tumour (Nephroblastoma).....	657
8.3.2	Pulmonary and Pleuropulmonary Blastoma.....	657
8.3.3	Hepatoblastoma	657
8.3.4	Pancreatoblastoma	658
8.4	Embryonal Sarcoma of Liver.....	658
8.5	Juxtaglomerular Cell Tumour	658
8.6	Cardiac Myxoma.....	659
8.7	Pneumocytoma (Sclerosing Haemangioma of Lung).....	659
8.8	Cellular Neurothekeoma	659
8.9	Amyloidoma	659
8.10	Malakoplakia.....	659
8.11	Bacillary Angiomatosis and Mycobacterial Spindle-Cell Pseudotumour	660
8.12	Rosai-Dorfman Disease	660
	References.....	665
	Index.....	671

Introduction

Brian Eyden

Department of Histopathology, Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, United Kingdom

1.1 Introductory Remarks

Electron microscopy is one of the great scientific techniques developed in the 20th century for the study of biological specimens. After the construction of the first electron microscope in the 1930s and subsequent refinement of design, the electron microscope was applied in the field of biology from the 1950s onwards: between the 1960s and 1980s, in particular, it revealed cells and tissues in all their astonishing structural detail, and this structure formed one of the foundations for revolutionising our understanding of cell function. In addition to new research discoveries, electron microscopy was found to be useful clinically. Almost all human diseases, where classical light microscope histopathology had been important for diagnosis and understanding their nature, provided examples where electron microscopy could promote diagnostic precision and advance this understanding. The main examples include: renal disease, neuromuscular disease, tumours, infectious microorganisms (viruses, bacteria, protozoa, fungi), immotile ciliary disease, spermatozoan abnormalities and centriolopathy, metabolic storage diseases, industrial diseases (for example, asbestosis), skin diseases (CADASIL [cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy], Ehlers-Danlos syndrome, bullous diseases) and haematology (anaemias and leukaemias).

1.2 Electron Microscopy Applied to Tumours

In the electron microscopic diagnosis of non-neoplastic disease, the emphasis is usually on identifying structural features within a known tissue, cell or organelle, which define or indicate a named pathological entity. This may be the basement membrane (basal lamina) in thin-membrane disease in glomerular pathology, the presence of abnormal Z-disks in nemaline myopathy, the abundant glycogen in Pompe's disease, or the absence of dynein arms in primary ciliary dyskinesia. The cellular differentiation in these examples is mostly known in advance, whereas in the diagnosis of tumours by electron microscopy the emphasis is rather more on determining cellular differentiation: while not the only one, this is a key factor for defining and contributing to tumour diagnosis and nomenclature.

The success of electron microscopy in helping to define tumour cell differentiation (and promoting diagnostic precision) is based on the fact that each cell has a characteristic ultrastructure by which it can be identified. This ultrastructure consists of distinctive and sometimes specific structures ("organelles"), and these are "retained" in the tumoral counterpart, even, sometimes, in poorly differentiated tumours. As an example, epidermal keratinocytes are characterised by tonofilaments, desmosomes and a basal lamina, and these cell structures, readily identified by electron microscopy, can also be seen in squamous-cell carcinoma. By this means, one would be able to distinguish, for example, a carcinoma from a lymphoma (Menasce and Eyden, 2005) or a spindle-cell melanoma from a sarcoma (Zelger *et al.*, 1997). See Table 1.1 for a more comprehensive list of the cell structures and organelles which characterise the main cell types and their tumours.

Table 1.1 Main cell structures defining differentiation in common tumours

Organelle	Differentiation
<i>Round/epithelioid cell tumours</i>	
Rough endoplasmic reticulum (rER)	Plasma cell
Melanosomes	Melanocytic
Neuroendocrine granules	Neuroendocrine/neuronal
Mucigen granules	Glandular epithelial
Desmosomes	Epithelial
Tonofibrils	Epithelial
Basal lamina	Epithelial
Lumina and microvilli	Glandular epithelial
Long, slender, smooth microvilli	Mesothelial
Cilia	Epithelial, ependymal
Mitochondria	Oncocytic (glandular epithelial) Steroidogenic ^a
Sarcomeres	Rhabdomyoblastic
Lysosomes	Histiocytic (macrophage)
Langerhans cell ('Birbeck') granules	Langerhans cell
Glycogen	Non-specific but distinctive for Ewing's Sarcoma
Lipid	Adipocytic Steroidogenic
Smooth endoplasmic reticulum (sER)	Steroidogenic
Cell processes	Glandular epithelial Mesothelial Histiocytic
<i>Spindle cell tumours</i>	
Desmosomes	Epithelial
Tonofibrils	Epithelial
Basal lamina ^{b,c}	Epithelial, Schwannian, Perineurial, Myogenic, Endothelial ("vascular")
Processes coated in lamina	Schwannian Perineurial cell
rER	Fibroblastic Myofibroblastic Osteoblastic Chondroblastic
Smooth-muscle myofilaments with focal densities ^d	Smooth-muscle (for example, leiomyoma and leiomyosarcoma) Myofibroblastic Pericytic
Fibronexus junctions	Myofibroblastic
Notes	^a with tubular cristae. ^b In spindle-cell tumours, other than carcinoma (for example, in Schwannian tumours or leiomyosarcoma), the term "basal" would be omitted since often the tumour cells have no identifiable apical-basal polarity to justify use of the term "basal". In these cells, it is best to use 'external lamina' or just 'lamina' ^c Desmosomes, tonofibrils and basal lamina are also indicative of myoepithelial differentiation (which co-expresses smooth-muscle myofilaments), tumours of which may have a cell morphology intermediate between round/epithelioid and spindled. ^d Smooth-muscle myofilaments in modestly developed amounts are common in a wide range of cell-types and tumours (Eyden, 2000). Lymphocytes and many lymphomas have the blandest of cytoplasm – one or two mitochondria or cisternae of rER, and no junctions or cell surface structures to speak of (see Chapter 5, Table 1.1)

1.3 Impact and Limitations of Immunohistochemistry

Electron microscopy is far from being the only technique for defining cellular differentiation, and in contemporary pathology, immunohistochemistry (IHC) is one of the most important ancillary techniques for providing this kind of information. IHC was originally based on identifying cell-specific or tumour-specific marker-proteins, and the convenience and early belief in antibody specificity impacted adversely on the practice of electron microscopy. Many clinical centres experienced a significant re-orientation of resources towards IHC at the expense of electron microscopy, and, as a result, in the 1980s, many small electron microscopy units closed down.

However, as the technique of IHC matured, it became clear that there are very few completely specific antibodies, a limitation it is sometimes necessary to compensate for by the use of large panels of antibodies in order to achieve a confident interpretation in the case of diagnostically problematical tumours. This lack of antibody specificity is one of several limitations of IHC (Table 1.2) which have enabled electron microscopy to survive in the diagnostic analysis of difficult tumours where uncertainty arises from conflicting clinical, histological or immunohistochemical findings. Unusual immunoreactivities can be encountered in tumours: cytokeratin positivity, traditionally the hallmark of carcinoma, can be seen in malignant melanoma, sarcoma and even lymphoma, while smooth-muscle actin can be expected, not only in smooth-muscle tumours, but in neoplasms showing pericytic, myoepithelial, myofibroblastic, endothelial cell and epithelial cell differentiation. In these instances, interpretation becomes uncertain and there is an opportunity for electron microscopy to play a role in clarifying the diagnosis.

1.4 Value of Electron Microscopy in Addition to Diagnosis

It is recognised that tumours are diagnosed with a certain level of confidence, and that this can be increased by electron microscopy. This is important primarily because there is nothing so important for the clinician managing a cancer patient as to have a diagnosis held with maximum confidence. However, it is also important for pathologists when they attend multidisciplinary team meetings and need to argue their case against conflicting opinions from other clinicians, such as radiologists and surgeons. The enhanced degree of diagnostic precision that electron microscopy can bring also protects pathologists against litigious patients or their relatives, and it has been used in cases where there has been suspected specimen contamination (Zuppan *et al.*, 1997).

Electron microscopy not only promotes the identification of named tumours to help clinicians manage patients, but gives pathologists a better understanding of the nature or cellular differentiation in tumours. Sometimes this information may not be diagnostically relevant and will appeal to the academically or research-orientated pathologist wishing to engage in publication. It can, however, also be helpful for junior pathologists who can see in electron microscopy images instructive correlations with the more familiar light microscopy images.

It should be noted that electron microscopy, like IHC, is a technique which provides information on differentiation, and not necessarily cell of origin. Many early papers refer to the value of electron microscopy in defining histogenesis (for example, Miettinen *et al.*, 1984), and yet, currently, our thinking is more towards the concept of a stem cell origin for many tumours (Dirks, 2010; Huysentruyt and Seyfried, 2010). Here, a stem cell, which under normal conditions would develop into a keratinocyte or melanocyte in the skin, for example, undergoes mutation and uncontrolled proliferation to produce a cutaneous squamous-cell carcinoma or malignant melanoma. Therefore, while the tumour may have many of the features of the tissue which is the intended (normal), non-mutated fate of a given stem cell, the tumour's cell of origin may be a quite different cell in terms of differentiation.

For those investigators engaged in cancer research, including the development of anti-cancer therapies (Gilloteaux *et al.*, 2001), electron microscopy of the source tissue – the *in vivo* tumour – provides a base-line for assessing the nature and cellular differentiation of their experimental material. Techniques include the use of cell lines or cells grown in culture (Nagashima *et al.*, 1990; Hara *et al.*, 1991; Carlén *et al.*, 1992; Hiraiwa *et al.*, 1997; Yufu *et al.*, 1999), the growth of solid tumour *in vitro* (Conley *et al.*, 1976; Xiang *et al.*, 2011), including the use of artificial matrices (Benton *et al.*, 2011), and the growth of tumour xenografted into experimental animals (Llombart-Bosch *et al.*, 1989; Hayashi and Akagi, 2000; Malham *et al.*, 2001; Hingorani *et al.*, 2011). Electron microscopy in these situations provides an opportunity of confirming the expression of cell features expected from the original *in vivo* tumour, but also of detecting culturing artefacts as part of the neo-differentiation that can occur when tumour cells are placed in a new (*in vitro*) environment. An example includes the bundles of myofilaments (Tsokos *et al.*, 1987), sometimes with fibronexus junctions (Lawton *et al.*, 1994), which form as cells attach to a physical substratum.